Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 5/20 | 0.35 |
| ▸ | CDK9 | P50750 | 5/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9897541 | 1.00 | CCNT1 (0.35) | CCNT1CDK9RBP4BRD4RIPK1 | |
| SCHEMBL9897162 | 1.00 | CCNT1 (0.35) | CCNT1CDK9RBP4BRD4RIPK1 | |
| SCHEMBL9897163 | 1.00 | CCNT1 (0.35) | CCNT1CDK9RBP4BRD4RIPK1 | |
| SCHEMBL9896795 | 0.95 | RBP4 (0.38) | CCNT1CDK9RBP4BRD4NPY5R | |
| SCHEMBL9896233 | 0.95 | RBP4 (0.38) | CCNT1CDK9RBP4BRD4NPY5R | |
| SCHEMBL9896234 | 0.95 | RBP4 (0.38) | CCNT1CDK9RBP4BRD4NPY5R | |
| SCHEMBL16553366 | 0.95 | RBP4 (0.38) | CCNT1CDK9RBP4BRD4NPY5R | |
| SCHEMBL9896793 | 0.95 | RBP4 (0.38) | CCNT1CDK9RBP4BRD4NPY5R | |
| SCHEMBL9897449 | 0.94 | CCNT1 (0.38) | CCNT1CDK9RBP4BRD4RIPK1 | |
| SCHEMBL9897451 | 0.94 | CCNT1 (0.38) | CCNT1CDK9RBP4BRD4RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8927557-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2470536-B1 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2014-11-12 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | CCNT1 1073/4885CDK9 641/4885RBP4 3017/4885 |
| US-20150073001-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE12, PDE5A, PDE4A | CCNT1 1056/4885CDK9 808/4885RBP4 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.